Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

WOODCLIFF LAKE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today filed with the U.S. Securities and Exchange Commission (SEC) its Form 10-Q for the third quarter of 2007. The filing of Par's Form 10-Q for this period had been delayed due to the work involved in restating its consolidated financial statements for certain prior periods, which were filed earlier this year. As a result of today's filing, the Company is now up-to-date on all of its reporting obligations with the SEC.

Third-Quarter and Nine-Month Results

For the third quarter ended September 29, 2007, Par reported total revenues of $212.7 million and net income of $1.3 million, or $0.04 per diluted share. This is compared with reported revenues of $174.0 million and net income of $4.4 million, or $0.13 per diluted share, for the same period in 2006. For the nine months ended September 29, 2007, Par reported total revenues of $614.5 million and net income of $45.6 million, or $1.30 per diluted share. This is compared with reported revenues of $541.5 million and net income $1.7 million, or $0.05 per diluted share, for 2006.

Third-quarter 2007 reported, or GAAP, results include $16.2 million of costs related to business development activities in support of the Company's branded division, Strativa, which are discussed in more detail below. Adjusting for this item, net income for the third quarter 2007 was $11.1 million, or $0.32 per diluted share. By comparison, third-quarter 2006 results included $7.1 million of severance costs and a $1.2 million net gain relating to the sale of certain product rights. Adjusting for these items, the Company posted net income of $8.0 million, or $0.23 per diluted share for the third-qu
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...rMadeinSupportofFeedingAmerica,sSNAPOutreachEffort...edingAmerica,thenation,slargesthunger-relieforgani...ofAmericaCharitableFoundationtosupportFeedingAmeri...lementalNutritionAssistanceProgram(SNAP),formerlyn...edingAmericafoodbanksimproveaccessandprovidepre-sc...
(Date:11/25/2009)... essential to normal human development - the Wnt/W... (EGFR) pathways - interact in ways that can promo... from The University of Texas M. D. Anderson Cance... Cell . , This newly characterized interaction i...ate with invasive cancer - activation of EGFR, ele...
(Date:11/25/2009)...n R. Kaplan, MD, FACP, a former Board Chair and on...ecame Los Angeles Biomedical Research Institute at...onored by the American College of Physicians for h...At its April 22, 2010 meeting in Toronto, the Amer... with the Ralph O. Claypoole Sr. Memorial Award fo...
(Date:11/25/2009)...at UT Southwestern Medical Center soon will begin ...ing in patients with upper spinal-cord injuries or...pendently. , UT Southwestern University Hospita... and one of 25 in the country currently equipped t...acing System. , The device is designed to give p...
(Date:11/25/2009)...ial function plays in insulin production , ...ondrial damage causes people with type 2 diabetes ...uld lead to new treatments, U.S. researchers say. ...vity. , The researchers found that when insulin...d to circulating insulin, it triggers a "molecular...
Breaking Medicine News(10 mins):Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 2Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 3Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:1 of LA BioMed's founders to be honored 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2
...sue alive, benefits other organs, study finds , ...ared to CPR alone, adding extracorporeal life supp...diac arrest, says a study by researchers at the Na...point blood travels through the catheter via a pum...
...premier research company in San Jose, releases sev...report provides a comprehensive insight into the p...luencing the market, growth drivers, and major cha... San Jose, CA (PRWEB) July 9, 20...
...ation that would cut $268 million,from Medicare Ad... Seniors across Minnesota,are speaking out against...n,legislation being considered in the U.S. Senate....are private,fee-for-service plans can operate, adv...
...dical care for the uninsured, human,services, and ...y 9 Blue Cross and Blue Shield,of Illinois (BCBSI...organizations in Illinois. In line with its missio... mostly on,community-based organizations that prov...
...experts at the University of Alabama at Birmingham...y Genomics-Based Medicine Project. The project is ...d academic centers working to improve treatment an...earch site in the Southeast. UAB is one of four co...
...r Engines, and Nominate Now at ..., one of the most trusted brands,for indigestion a...rch for,one lucky fan to serve as the Grand Marsha...cgi-bin/prnh/20080709/AQW525 ), "TUMS, and the al...
Other Medicine News:Health News:ELS Plus CPR Boosts Blood Flow After Cardiac Arrest 2Health News:Global Industry Analysts' Releases a Series of Medical Market Research Reports 2Health News:Global Industry Analysts' Releases a Series of Medical Market Research Reports 3Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 3Health News:UAB joins elite brain cancer research group 2Health News:TUMS Announces Nationwide Search for Grand Marshal at TUMS QuikPak 500 2
(Date:11/24/2009)...a/--ChindexInternational,Inc.,("Chindex")(Nasdaq: ...n,healthcareproductsandservicesinthePeople,sRepubl...he21stAnnualPiperJaffray,"Unplugged"HealthCareConf...eHotel. , Managementiscurrentlyscheduledtopre...e-on-onemeetingsthroughouttheday.Awebcast,ofthepre...
(Date:11/24/2009)...ll/--AnadysPharmaceuticals,Inc.(Nasdaq: ANDS )anno...frayHealthcareConferenceonTuesday,December1,2009at...tTheNewYorkPalaceHotel.SteveWorland,Ph.D.,Presiden...rviewofAnadysanditsclinicaldevelopmentprograms,ANA...simultaneouslywebcastandcanbeaccessedontheInvestor...
(Date:11/24/2009)...-ZargisMedicalCorp.,asubsidiaryofSpeedusCorp.(Nasd...(NYSE: SI ),todayannouncedthatitsZargisCardioscand...TheEarlyShow duringasegmentinwhichMarkJannot,theed...productsfromthepublication,s2009"BestofWhat,sNew"a...ionmorningnewstalkshowbroadcastbyCBSfromNewYorkCit...
Breaking Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Cystic Fibrosis Treatment May Cause Hearing Loss 50673 1Cardinal Health Appoints Bruce Downey to Board of Directors 3B John McCoy Retires From Board After 22 Years 50670 1Cardinal Health Appoints Bruce Downey to Board of Directors 3B John McCoy Retires From Board After 22 Years 50670 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 1CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 3
...mmary: Proprietary DNA delivery technology enables...cells - reduces,atherosclerosis progression in mou...WIRE)--Mar 26, 2007 - Research conducted,at Clevel...lege of,Cardiology,s 58th Annual Scientific Sessio...ing the anti-inflammatory protein,interferon-beta ...
...ISIS 301012 coadministered with statins for only f...the levels achieved with,statins alone, with simil..., NEW ORLEANS and CARLSBAD, Calif., March 26, 2007...nc. announced new,results from its Phase 2 clinica... presented today at the of Cardiology,Annual Scien...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
Full Handle Laseredge Implant Blade Knife, 3.2 mm round tip
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up
Full Handle Laseredge Crescent Blade Knife, angled bevel down
Medicine Products: